Inhibition of histone deacetylase protects the retina from ischemic injury

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 7, 2010, Pages 3639-3645

  Crosson, Craig E ^a   Mani, Santhosh K ^b   Husain, Shahid ^a   Alsarraf, Oday ^a   Menick, Donald R ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; HISTONE; HYDROXAMIC ACID; NEUROPROTECTIVE AGENT;

A WAVE; ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; B WAVE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; ENZYME INHIBITION; ENZYME RELEASE; FEMALE; GENE EXPRESSION; HISTONE ACETYLATION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; RETINA INJURY; RETINA ISCHEMIA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BROWN NORWAY RAT; DRUG EFFECT; ENZYMOLOGY; METABOLISM; REPERFUSION INJURY; RETINA; RETINA DISEASE;

ACETYLATION; ANIMALS; BLOTTING, WESTERN; ELECTRORETINOGRAPHY; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED BN; REPERFUSION INJURY; RETINA; RETINAL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955896784     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4538     Document Type: Article

References (45)

1. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res. 2004;23:91-147.
2. Li B, Roth S. Retinal ischemic preconditioning in the rat: requirement for adenosine and repetitive induction. Invest Ophthalmol Vis Sci. 1999;40:1200-1216.
3. Husain S, Potter DE, Crosson CE. Opioid receptor-activation: retina protected from ischemic injury. Invest Ophthalmol Vis Sci. 2009; 50:3853-3859
4. Li Y, Roth S, Laser M, Ma JX, Crosson CE. Retinal preconditioning and the induction of heat-shock protein 27. Invest Ophthalmol Vis Sci. 2003;44:1299-1304.
5. Li Y, Schlamp CL, Poulsen GL, Jackson MW, Griep AE, Nickells RW. p53 Regulates apoptotic retinal ganglion cell death induced by N-methyl-D-aspartate. Mol Vis. 2002;8:341-350.
6. Libby RT, Li Y, Savinova OV, et al. Susceptibility to neurodegen-eration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005;1:17-26.
7. Casson RJ, Wood JP, Melena J, Chidlow G, Osborne NN. The effect of ischemic preconditioning on light-induced photoreceptor injury. Invest Ophthalmol Vis Sci. 2003;44:1348-1354.
8. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51.
9. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol. 2005;25:2873-2884.
10. Huang L. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.J Cell Physiol. 2006;209:611-616.
11. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110:479-488.
12. 2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. JNeurosci. 2006;26:11174-11186.
13. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. JNeurosci. 2003;23: 9418-9427.
14. Gardian G, Browne SE, Choi DK, et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem. 2005;280:556-563.
15. Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neuro-biol Dis. 2006;22:40-49
16. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA. 2001;98:9808-9813
17. Faraco G, Pancani T, Formentini L, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. MolPharmacol. 2006;70:1876-1884.
18. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science. 2005;307:269-273.
19. Quivy V, Van Lint C. Regulation at multiple levels of NF-κB-medi-ated transactivation by protein acetylation. Biochem Pharmacol. 2004;68:1221-1229
20. Nasu Y, Nishida K, Miyazawa S, et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 2008;16:723-732.
21. Young DA, Lakey RL, Pennington CJ, et al. Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther. 2005; 7:R503-R512.
22. Wang X, Song Y, Jacobi JL, Tuan RS. Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors. 2009;27:40-49.
23. Chen B, Cepko CL. Requirement of histone deacetylase activity for the expression of critical photoreceptor genes. BMC Dev Biol. 2007;7:78-89.
24. Wallace DM, Donovan M, Cotter TG. Histone deacetylase activity regulates Apaf-1 and caspase 3 expression in the developing mouse retina. Invest Ophthalmol Vis Sci. 2006;47:2765-2772.
25. Schwechter BR, Millet LE, Levin LA. Histone deacetylase inhibition-mediated differentiation of RGC-5 cells and interaction with survival. Invest Ophthalmol Vis Sci. 2007;48:2845-2857.
26. Whitlock NA, Agarwal N, Ma JX, Crosson CE. Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci. 2005;46:1092-1098.
27. Yang P. Purification of astrocytes from adult human optic nerve heads by immunopanning. Brain Res Brain Res Protoc. 2003;12: 67-76.
28. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, Castro-Villegas MC, Gallardo-Galera JM, Collantes-Estevez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin. 2004;20:155-157.
29. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:1366-1369.
30. Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001;42:1787-1794.
31. Dreixler JC, Hagevik S, Hemmert JW, Shaikh AR, Rosenbaum DM, Roth S. Involvement of erythropoietin in retinal ischemic preconditioning. Anesthesiology. 2009;110:774-780.
32. Peng PH, Huang HS, Lee YJ, Chen YS, Ma MC. Novel role for the delta-opioid receptor in hypoxic preconditioning in rat retinas. JNeurochem. 2009;108:741-754.
33. Thiersch M, Raffelsberger W, Frigg R, et al. Analysis of the retinal gene expression profile after hypoxic preconditioning identifies candidate genes for neuroprotection. BMC Genomics. 2008;9:73-86.
34. Kamphuis W, Dijk F, Bergen AA. Ischemic preconditioning alters the pattern of gene expression changes in response to full retinal ischemia. Mol Vis. 2007;13:1892-1901.
35. Zhu Y, Zhang Y, Ojwang BA, Brantley MA, Gidday JM. Long-term tolerance to retinal ischemia by repetitive hypoxic preconditioning: role of HIF-1a and heme oxygenase-1. Invest Ophthalmol Vis Sci. 2007;48:1735-1743.
36. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine seacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9:206-218.
37. Walkinshaw DR, Tahmasebi S, Bertos NR, Yang XJ. Histone deacetylases as transducers and targets of nuclear signaling. J Cell Biochem. 2008;104:1541-1552.
38. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Histone acetylation and the cell-cycle in cancer. Front Biosci. 2001;6:D610-D629.
39. Zhang ZK, Davies KP, Allen J, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol. 2002;22: 5975-5988.
40. Kim J, Sif S, Jones B, et al. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. Immunity. 1999;10:345-355
41. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature. 2000; 408:377-381.
42. Berger S, Savitz SI, Nijhawan S, et al. Deleterious role of TNF-alpha in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2008;49:3605-3610.
43. Mali RS, Cheng M, Chintala SK. Intravenous injection of a membrane depolarization agent causes retinal degeneration via matrix metalloproteinase-9. Invest Ophthalmol Vis Sci. 2005;46:2125-2132.
44. Manabe S, Gu Z, Lipton SA. Activation of matrix metalloproteinase-9 via neuronal nitric oxide synthase contributes to NMDA-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2005;46:4747-4753.
45. 2+ homeostasis. Brain Res. 2008;1233:63-78.